Fresenius SE & Co. KGaA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Sen
- Full Time Employees
- 178,394
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Address
- Else-Kroener-Strasse 1 Bad Homburg HE Germany 61352
- IPO Date
- Nov 9, 1998
- Website
- fresenius.de
- Similar Companies
- Business
- Fresenius SE & Co. KGaA operates as a global healthcare enterprise, providing vital goods and services for dialysis, hospital care, and outpatient medical treatments. The company is structured around key operational areas, which include Fresenius Kabi, Fresenius Helios, and its investment in Fresenius Medical Care, alongside strategic adjustments to Fresenius Vamed. The Fresenius Medical Care entity delivers products and comprehensive services for individuals dealing with chronic kidney conditions, maintaining its position as a world leader in this specialized field. This segment offers an extensive range of items such as advanced dialyzers, hemodialysis equipment, associated disposable medical products, and diverse dialysis-related care, including an expansion of home dialysis options. Notably, in February 2024, the 5008X Hemodialysis System received FDA clearance, paving the way for hemodiafiltration therapy to be introduced in its U.S. clinics from 2025. Fresenius SE & Co. KGaA holds a 32% ownership stake in Fresenius Medical Care. The Fresenius Kabi division focuses on treatments and essential care for critically and chronically ill patients. Its diverse portfolio features biopharmaceuticals, including biosimilars for autoimmune disorders and oncology, alongside a wide array of intravenous generic medications spanning oncology, anesthetics, analgesics, anti-infectives, and critical care. Additionally, it offers parenteral and enteral nutrition products, infusion solutions, blood volume substitutes, and medical technology items like infusion pumps, apheresis machines, and cell therapy devices. Within Fresenius Helios, the company operates as Europe's foremost private hospital network. In Germany, this encompasses more than 80 hospitals, approximately 220 medical care centers, and various prevention and occupational health facilities. Its Spanish operations manage 50 hospitals, around 130 outpatient centers, and over 300 occupational health management sites, with further hospital presence in Latin America. The fertility services group Eugin was divested on January 31, 2024. The Fresenius Vamed segment has undergone a structured exit and restructuring as part of the company's #FutureFresenius strategy. While its rehabilitation business was divested, Fresenius retains a minority stake. Vamed's hospital services operations, known as High-End Services, are being integrated directly into the Fresenius Group as Fresenius Health Services (FHS) starting January 1, 2025. This new entity will offer comprehensive support for healthcare facilities, including managing technical infrastructure, medical technology, operating technology, and sterile supply. Fresenius continues to scale back Vamed's international project business. Founded in 1912, Fresenius SE & Co. KGaA is headquartered in Bad Homburg vor der Höhe, Germany. The company's ongoing strategy prioritizes simplification, performance acceleration, and a sharper focus across its core platforms: (Bio)Pharma including clinical nutrition, MedTech, and Care Provision.
Company News
Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Still a Buy?
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
All You Need to Know About Fresenius SE & Co. (FSNUY) Rating Upgrade to Buy
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Fresenius SE & Co. KGaA (FSNUY) Q2 2026 Earnings Call Transcript
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
Fresenius SE & Co. KGaA (FSNUY) Q1 2026 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fresenius SE & Co. (OTCMKTS:FSNUY) vs. U.S. Physical Therapy (NYSE:USPH) Head to Head Review
Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript
Financial Review: Fresenius SE & Co. (OTCMKTS:FSNUY) vs. DaVita (NYSE:DVA)
Fresenius SE & Co. KGaA (FSNUY) Q3 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q2 2025 Earnings Call Transcript